Mr. Pomeranz serves as Chief Executive Officer. Prior to joining Motus GI Medical Technologies Ltd., Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a start-up company that developed a unique drug eluting stent platform. From 2007 to 2008 Mr. Pomeranz was the Vice President of Research and Development at Prescient Medical, Inc. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson & Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create cross-functional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporation. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. Mr. Pomeranz was selected as a director due to his history as a director of Motus GI Medical Technologies Ltd. and his business and leadership experience in the medical technology sector; his broad scientific background is also seen as an asset to us.
Mrs. Ram brings to Motus GI over 17 years of financial and operational leadership of international technology and medical device companies. Involved in strategic decisions and processes through the company’s various life cycles from startups to well established public companies. Highly experienced in establishing the necessary process in accordance with company needs and business phase. Prior to joining Motus GI in April 2018, Mrs. Ram served as the Director of Finance, supply chain, and site manager at EndoChoice, managing EndoChoice Israeli site finance, supply chain, and IT departments. Earlier, she served as Global Director Operation Controller at Given Imaging, responsible for all financial aspects of company global operations and R&D activities. Mrs. Ram earned her B.A. in Finance and Sociology at ‘Bar Ilan’ University and M.A. in Actuary – Haifa University.
Mr. Amor has served as our Chief Accounting Officer since June 2023, where he oversees corporate accounting, finance, internal audit, and corporate governance matters. Since 2019, Mr. Amor has served as the Company’s Global Director of Corporate Finance and Accounting, where he oversaw all facets of the Company’s global accounting functions, as well as the preparation of internal and external financial reporting.
Mr. Amor brings extensive corporate finance and accounting expertise, most notably over a decade of leadership experience at public biotechnology companies and public accounting to Motus. Prior to joining the Company in 2019, Mr. Amor held leadership roles as Associate Director of Accounting and SEC Reporting at Kaleido Biosciences (NASDAQ: KLDO), where he oversaw the SEC reporting and technical accounting functions through the company’s IPO and through its continued growth. Earlier, from 2016-2019, he served as the Manager of SEC Reporting and Technical Accounting at CRISPR Therapeutics AG (NASDAQ: CRSP), where he positioned the SEC reporting, finance, investor relations and technical accounting functions from IPO to support the company’s continued growth. Prior to 2016, he held several leadership positions at Athenahealth, Inc (NASDAQ: ATHN) and the Medical College of Wisconsin. Mr. Amor started his career in public accounting at KPMG, LLP and Ernst & Young LLP in the healthcare and life sciences practices.
Mr. Amor holds an MS in Professional Accounting and an MBA in finance from Northeastern University, as well as an MS in Medical Epidemiology from the Medical College of Wisconsin and a BS in Genetics from the University of Wisconsin- Madison. Mr. Amor is a Certified Public Accountant.
Mr. Gnagi has served in various market development and sales leadership roles within MotusGI. During his tenure, he has helped identify new sales channels to drive further penetration of the Pure-Vu system. He has over 20 years of medical device sales leadership experience in launching new products and building robust sales teams.
Most recently, he was with Medtronic GI Solutions (NYSE: MDT) where he led multiple sales teams. Mr Gnagi was an integral part of the sales organization of BARRX Medical when it was purchased in 2011 by Covidien, integrated with Given Imaging and later acquired by Medtronic.
Prior to BARRX, Mr. Gnagi spent 6 years with Boston Scientific (NYSE: BSX) Women’s Health, a new division born from the Urology Division. He served in a variety of sales, training, sales management, market development and specialist roles.
Mr Gnagi holds a BA from University of Wisconsin-Milwaukee.